|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||27.48 - 28.58|
|52-week range||27.48 - 28.58|
|Beta (5Y monthly)||1.89|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.